Effect of concurrent chemoradiotherapy with cisplatin and 5-fluorouracil for FIGO stage IIB of the uterine cervix.
- Author:
Hyun Young LEE
1
;
Kwang Beom LEE
;
Jin Woo SHIN
;
Chan Yong PARK
;
Seok Ho LEE
;
Kyu Chan LEE
;
Jong Min LEE
Author Information
1. Department of Obstetrics and Gynecology, Gil Medical Center, Gachon University of Medicine and Science, Incheon, Korea.
- Publication Type:Original Article
- Keywords:
Concurrent chemoradiotherapy;
Consolidation chemotherapy;
Cervical carcinoma
- MeSH:
Cervix Uteri*;
Chemoradiotherapy*;
Cisplatin*;
Consolidation Chemotherapy;
Disease-Free Survival;
Drug Therapy;
Female;
Fluorouracil*;
Follow-Up Studies;
Humans;
Retrospective Studies;
Survival Rate;
Uterine Cervical Neoplasms;
Uterus
- From:Korean Journal of Gynecologic Oncology
2007;18(1):32-38
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
OBJECTIVE: To determine effect of concurrent chemoradiotherapy (CCRT) in treatment of FIGO stage IIB cervical cancer the uterus and of consolidation chemotherapy using same chemotherpeutic regimens. METHODS: The study population consisted of total number of 41 patients diagnosed as having cervical cancer FIGO stage IIB between January 1999 and December 2003 and treated with CCRT. We were divided into 2 groups according to number of cycles of chemotherapy received [e.g., < or =3 (n=19, cases) cycles versus >3 (n=22, controls) cycles]. Both groups had received the chemotherapeutic regimens which consist of cisplatin 60 mg/m2 followed by five consecutive daily infusions of 5-fluorouracil (5-FU) 1,000 mg/m2 every 3 weeks. RESULTS: 5 years survival rate and 3 years progression free survival are 80.1% and 60.6% in 45 months median follow up duration (range 6-81 months). The median duration of follow up for case and control is 42 months (range 6-81 months) and 52.5 months (range 11-74 months) respectively (p=0.89). Both progression free survival rate (p=0.77) and survival rate (p=0.39) of the groups were revealed to be without statistical significance. CONCLUSION: This study shows similar results to compare with previous CCRT reports and that CCRT is primary treatment of cervical cancer IIB.We may not improve remarkably survival with many chemotherapy cycles. But because of small population and retrospective study, further study of a large number of patients,prospective and long term follow up will be necessary to test the efficacy of the consolidation chemotherapy.
